drugset / Trial / NCT07136285
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Phase 1/2
Recruiting
27 enrolled
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Genelux GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
Timeline
- Start
- 2023-07-24
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olvimulogene nanivacirepvec | Other / unclassified | — | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |